Inhibition of Osteoclast Differentiation by Ginsenoside Rg3 in RAW264.7 Cells via RANKL, JNK and p38 MAPK Pathways Through a Modulation of Cathepsin K: An in Silico and in Vitro Study

Phytotherapy Research

Volumn 29, Issue 9, 2015, Pages 1286-1294

  Siddiqi, Muhammad Hanif ^a   Siddiqi, Muhammad Zubair ^a   Kang, Sera ^a   Noh, Hae Yong ^a   Ahn, Sungeun ^a   Simu, Shakina Yesmin ^a   Aziz, Mohamed Antar ^a   Sathishkumar, Natarajan ^a   Jiménez Pérez, Zuly Elizabeth ^a   Yang, Deok Chun ^a  

^a Kyung Hee University   (South Korea)

Author keywords

bone resorption; ginsenosides; osteoclast; p38 MAPK ERK NF kB RAW264.7 cells; RANKL

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; CATHEPSIN K; GINSENOSIDE RG 3; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; ODANACATIB; OSTEOCLAST DIFFERENTIATION FACTOR; STRESS ACTIVATED PROTEIN KINASE;

ANIMAL CELL; ARTICLE; COMPUTER MODEL; CONTROLLED STUDY; DOSE RESPONSE; DOWN REGULATION; DRUG STRUCTURE; ENZYME ACTIVITY; IN VITRO STUDY; MOLECULAR DOCKING; MOUSE; MULTINUCLEAR CELL; NONHUMAN; OSSIFICATION; OSTEOCLASTOGENESIS; OSTEOLYSIS; OSTEOPOROSIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION;

EID: 84941173752     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5374     Document Type: Article

References (44)

1. Asagiri M, Sato K, Usami T, et al., 2005. Autoamplification of NFATc1 expression determines its essential role in bone homeostasis. J Exp Med 202: 1261-1269.
2. Bai CX, Sunami A, Namiki T, et al., 2003. Electrophysiological effects of ginseng and ginsenoside Re in guinea pig ventricular myocytes. Eur J Pharmacol 476: 35-44.
3. Bharti AC, Takada Y, Aggarwal BB,. 2004. Curcumin (diferuloylmethane) inhibits receptor activator of NF-kappa B ligand-induced NF-kappa B activation in osteoclast precursors and suppresses osteoclastogenesis. J Immunol 172: 5940-5947.
4. Body JJ,. 2002. Calcitonin for the long-term prevention and treatment of postmenopausal osteoporosis. Bone 30: 75S-79S.
5. Boyle WJ, Simonet WS, Lacey DL,. 2003. Osteoclast differentiation and activation. Nature 423: 337-342.
6. Bromme D, Okamoto K,. 1995. Human cathepsin O2, a novel cysteine protease highly expressed in osteoclastomas and ovary molecular cloning, sequencing and tissue distribution. Biol Chem Hoppe Seyler 376: 379-384.
7. Bromme D, Okamoto K, Wang BB, et al., 1996. Human cathepsin O2, a matrix protein-degrading cysteine protease expressed in osteoclasts. Functional expression of human cathepsin O2 in Spodoptera frugiperda and characterization of the enzyme. J Biol Chem 271: 2126-2132.
8. Drake FH, Dodds RA, James IE, et al., 1996. Cathepsin K, but not cathepsins B, L, or S, is abundantly expressed in human osteoclasts. J Biol Chem 271: 12511-12516.
9. Franzoso G, Carlson L, Xing L, et al., 1997. Requirement for NF-kappaB in osteoclast and B-cell development. Genes Dev 11: 3482-3496.
10. Fujisaki K, Tanabe N, Suzuki N, et al., 2007. Receptor activator of NF-kappaB ligand induces the expression of carbonic anhydrase II, cathepsin K, and matrix metalloproteinase-9 in osteoclast precursor RAW264.7 cells. Life Sci 80: 1311-1318.
11. Gingery A, Bradley EW, Pederson L, et al., 2008. TGF-beta coordinately activates TAK1/MEK/AKT/NFkB and SMAD pathways to promote osteoclast survival. Exp Cell Res 314: 2725-2738.
12. Gohda J, Akiyama T, Koga T, et al., 2005. RANK-mediated amplification of TRAF6 signaling leads to NFATc1 induction during osteoclastogenesis. EMBO J 24: 790-799.
13. He L, Lee J, Jang JH, et al., 2012. Ginsenoside Rh2 inhibits osteoclastogenesis through down-regulation of NF-kappaB, NFATc1 and c-Fos. Bone 50: 1207-1213.
14. Hsu H, Lacey DL, Dunstan CR, et al., 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci U S A 96: 3540-3545.
15. Igarashi Y, Lee MY, Matsuzaki S,. 2002. Acid phosphatases as markers of bone metabolism. J Chromatogr B Analyt Technol Biomed Life Sci 781: 345-358.
16. Iotsova V, Caamano J, Loy J, et al., 1997. Osteopetrosis in mice lacking NF-kappaB1 and NF-kappaB2. Nat Med 3: 1285-1289.
17. Kanno S, Hirano S, Kayama F,. 2004. Effects of the phytoestrogen coumestrol on RANK-ligand-induced differentiation of osteoclasts. Toxicology 203: 211-220.
18. Kim MH, Ryu SY, Bae MA, et al., 2008. Baicalein inhibits osteoclast differentiation and induces mature osteoclast apoptosis. Food Chem Toxicol 46: 3375-3382.
19. Kousteni S, Bellido T, Plotkin LI, et al., 2001. Nongenotropic, sex-nonspecific signaling through the estrogen or androgen receptors: dissociation from transcriptional activity. Cell 104: 719-730.
20. Lee ZH, Kim HH,. 2003. Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 305: 211-214.
21. Lee SE, Woo KM, Kim SY, et al., 2002. The phosphatidylinositol 3-kinase, p38, and extracellular signal-regulated kinase pathways are involved in osteoclast differentiation. Bone 30: 71-77.
22. Long CL, Berry WL, Zhao Y, et al., 2012. E proteins regulate osteoclast maturation and survival. J Bone Miner Res 27: 2476-2489.
23. Luo X, Wang CZ, Chen J, et al., 2008. Characterization of gene expression regulated by American ginseng and ginsenoside Rg3 in human colorectal cancer cells. Int J Oncol 32: 975-983.
24. Miyazaki T, Katagiri H, Kanegae Y, et al., 2000. Reciprocal role of ERK and NF-kappaB pathways in survival and activation of osteoclasts. J Cell Biol 148: 333-342.
25. Morris GM, Goodsell DS, Halliday RS, et al., 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J Comput Chem 19: 1639-1662.
26. O'Boyle NM, Banck M, James CA, Morley C, Vandermeersch T, Hutchison GR,. 2011. Open babel: an open chemical toolbox. J Cheminf 3: 33.
27. O'Regan RM, Gradishar WJ,. 2001. Selective estrogen-receptor modulators in 2001. Oncology 15: 1177-1185.
28. Parfitt AM,. 1987. Bone remodeling and bone loss: understanding the pathophysiology of osteoporosis. Clin Obstet Gynecol 30: 789-811.
29. Poroikov VV, Filimonov DA, Ihlenfeldt WD, et al., 2003. PASS biological activity spectrum predictions in the enhanced open NCI database browser. J Chem Inf Comput Sci 43: 228-236.
30. Ravikumar M, Pavan S, Bairy S, et al., 2008. Virtual screening of cathepsin k inhibitors using docking and pharmacophore models. Chem Biol Drug Des 72: 79-90.
31. Rhim H, Kim H, Lee DY, et al., 2002. Ginseng and ginsenoside Rg3, a newly identified active ingredient of ginseng, modulate Ca2+ channel currents in rat sensory neurons. Eur J Pharmacol 436: 151-158.
32. Rodan GA, Martin TJ,. 2000. Therapeutic approaches to bone diseases. Science 289: 1508-1514.
33. Siddiqi MH, Siddiqi MZ, Ahn S, et al., 2014a. Stimulative effect of ginsenosides Rg5:Rk1 on murine osteoblastic MC3T3-E1 cells. Phytother Res 28: 1447-1455.
34. Siddiqi MH, Siddiqi MZ, Ahn S, et al., 2014b. Ginsenoside Rh1 induces mouse osteoblast growth and differentiation through the bone morphogenetic protein 2/runt-related gene 2 signalling pathway. J Pharm Pharmacol 66: 1763-1773.
35. Takahashi N, Yamana H, Yoshiki S, et al., 1988. Osteoclast-like cell formation and its regulation by osteotropic hormones in mouse bone marrow cultures. Endocrinology 122: 1373-1382.
36. Takatsuna H, Asagiri M, Kubota T, et al., 2005. Inhibition of RANKL-induced osteoclastogenesis by (-)-DHMEQ, a novel NF-kappaB inhibitor, through downregulation of NFATc1. J Bone Miner Res 20: 653-662.
37. Takayanagi H,. 2007. Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems. Nat Rev Immunol 7: 292-304.
38. Teitelbaum SL, Ross FP,. 2003. Genetic regulation of osteoclast development and function. Nat Rev Genet 4: 638-649.
39. Weitzmann MN, Pacifici R,. 2006. Estrogen regulation of immune cell bone interactions. Ann N Y Acad Sci 1068: 256-274.
40. Wilson SR, Peters C, Saftig P, Bromme D,. 2009. Cathepsin K activity-dependent regulation of osteoclast actin ring formation and bone resorption. J Biol Chem 284: 2584-2592.
41. Xia L, Kilb J, Wex H, et al., 1999. Localization of rat cathepsin K in osteoclasts and resorption pits: inhibition of bone resorption and cathepsin K-activity by peptidyl vinyl sulfones. Biol Chem 380: 679-687.
42. Xu TM, Xin Y, Cui MH, et al., 2007. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chin Med J (Engl) 120: 584-588.
43. Yamashita T, Yao Z, Li F, et al., 2007. NF-kappaB p50 and p52 regulate receptor activator of NF-kappaB ligand (RANKL) and tumor necrosis factor-induced osteoclast precursor differentiation by activating c-Fos and NFATc1. J Biol Chem 282: 18245-18253.
44. Yue PY, Wong DY, Wu PK, et al., 2006. The angiosuppressive effects of 20(R)- ginsenoside Rg3. Biochem Pharmacol 72: 437-445.